DGAP-Adhoc: Fresenius SE: Record financial results in 2009 − All financial targets met or exceeded − Positive outlook for 2010

| Source: EQS Group AG EQS Group AG 

Fresenius SE / Final Results

24.02.2010 07:05 

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Record financial results in 2009 − All financial targets met or exceeded −
Positive outlook for 2010

Group sales increased by 13% in constant currency and by 15% at actual
rates to EUR14,164 million (2008: EUR12,336 million). Organic sales growth
was 8%. Acquisitions contributed a further 5%. Currency translation had a
positive impact of 2%.

Group operating income (EBIT) grew by 17% in constant currency and by 19%
at actual rates to EUR2,054 million (2008 adjusted for special items
related to the acquisition of APP Pharmaceuticals: EUR1,727 million).

Adjusted Group net income* grew both in constant currency and at actual
rates by 14% to EUR514 million (2008 adjusted for special items related to
the acquisition of APP Pharmaceuticals: EUR450 million). Adjusted earnings
per ordinary share increased to EUR3.18 and adjusted earnings per
preference share increased to EUR3.19 (2008 adjusted: ordinary share
EUR2.85, preference share EUR2.86). This represents an increase of 12% for
both share classes.

Net income** (including special items) was EUR494 million or EUR3.06 per
ordinary share and EUR3.07 per preference share.

Based on the excellent financial results the Management Board will propose
to the Supervisory Board a dividend increase of 7% to EUR0.75 per ordinary
share (2008: EUR0.70) and EUR0.76 per preference share (2008: EUR0.71).

For 2010, Fresenius projects further improvements in its financial results:
Sales growth in constant currency is projected to be in a 7 to 9% range.
Adjusted net income* is expected to increase by 8 to 10% in constant
currency.

The Group's US GAAP financial results as of December 31, 2009 and as of
December 31, 2008 include the effects of mark-to-market accounting of the
Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR)
related to the acquisition of APP Pharmaceuticals. Adjusted earnings
represent the Group's business operations in the reporting period. In
addition, the Group's US GAAP financial statements as of December 31, 2008
include several special items related to the acquisition of APP
Pharmaceuticals.


*Net income attributable to Fresenius SE; adjusted for the effects of
mark-to-market accounting of the Mandatory Exchangeable Bonds (MEB) and the
Contingent Value Rights (CVR) related to the acquisition of APP
Pharmaceuticals. Both are non-cash items.

**Net income attributable to Fresenius SE


(Financial statements according to US GAAP)

The Management Board

Bad Homburg v.d.H., February 24, 2010

End of note


24.02.2010 07:05 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]

---------------------------------------------------------------------------
 
Language:     English
Company:      Fresenius SE
              Else-Kröner-Straße 1
              61352 Bad Homburg v.d.H.
              Deutschland
Phone:        +49 (0)6172 608-2485
Fax:          +49 (0)6172 608-2488
E-mail:       ir-fre@fresenius.com
Internet:     www.fresenius.com
ISIN:         DE0005785638, DE0005785604
WKN:          578563, 578560
Indices:      DAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf,
              München; Freiverkehr in Berlin, Hannover, Stuttgart, Hamburg;
              Terminbörse EUREX
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------